Ryan et al., 2013 - Google Patents
Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcriptionRyan et al., 2013
View HTML- Document ID
- 3079012215711384988
- Author
- Ryan S
- Dolatabadi N
- Chan S
- Zhang X
- Akhtar M
- Parker J
- Soldner F
- Sunico C
- Nagar S
- Talantova M
- Lee B
- Lopez K
- Nutter A
- Shan B
- Molokanova E
- Zhang Y
- Han X
- Nakamura T
- Masliah E
- Yates J
- Nakanishi N
- Andreyev A
- Okamoto S
- Jaenisch R
- Ambasudhan R
- Lipton S
- Publication year
- Publication venue
- Cell
External Links
Snippet
Parkinson's disease (PD) is characterized by loss of A9 dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). An association has been reported between PD and exposure to mitochondrial toxins, including environmental pesticides paraquat, maneb, and …
- 230000035897 transcription 0 title description 8
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ryan et al. | Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription | |
Cheng et al. | The emerging roles of protein homeostasis‐governing pathways in Alzheimer's disease | |
Puspita et al. | Oxidative stress and cellular pathologies in Parkinson’s disease | |
Che et al. | Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M1 polarization | |
Lee et al. | Modeling ALS and FTD with iPSC-derived neurons | |
Chiabrando et al. | Unraveling the role of heme in neurodegeneration | |
Bretaud et al. | p53‐dependent neuronal cell death in a DJ‐1‐deficient zebrafish model of Parkinson's disease | |
Sunico et al. | S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease | |
Bahi | Hippocampal BDNF overexpression or microR124a silencing reduces anxiety-and autism-like behaviors in rats | |
Jia et al. | Rheb-regulated mitochondrial pyruvate metabolism of Schwann cells linked to axon stability | |
Zhang et al. | Generation of a novel mouse model of Parkinson’s disease via targeted knockdown of glutamate transporter GLT-1 in the substantia nigra | |
Golsorkhdan et al. | Methamphetamine administration impairs behavior, memory and underlying signaling pathways in the hippocampus | |
Cao et al. | Induced pluripotent stem cells for disease modeling and drug discovery in neurodegenerative diseases | |
Khlghatyan et al. | Fxr1 regulates sleep and synaptic homeostasis | |
Jiang et al. | MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1 | |
Fame et al. | Mitochondria in early forebrain development: from neurulation to mid-corticogenesis | |
Liu et al. | miR‑134‑5p/Foxp2/Syn1 is involved in cognitive impairment in an early vascular dementia rat model | |
Wu et al. | Inhibition of HDAC4 attenuated JNK/c-Jun-dependent neuronal apoptosis and early brain injury following subarachnoid hemorrhage by transcriptionally suppressing MKK7 | |
Brunialti et al. | Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons | |
Liu et al. | The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing | |
More et al. | Emerging preclinical pharmacological targets for Parkinson's disease | |
Zhang et al. | TMEM106B regulates microglial proliferation and survival in response to demyelination | |
Ray et al. | Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategy | |
Kim et al. | Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson’s disease | |
Huang et al. | The cold‐inducible RNA‐binding protein—Thioredoxin 1 pathway ameliorates mitochondrial dysfunction and mitochondrial dynamin‐related protein 1 level in the hippocampus of aged mice with perioperative neurocognitive dysfunction |